Thus far, genome-wide association studies (GWAS) have identified 20 common, genome-wide significant melanoma susceptibility loci 1-9 , most of which do not seem to be explained by protein-coding variants. A subset of these loci harbor known pigmentation-related genes that mediate melanoma-associated phenotypes such as eye, hair, and skin color. Several loci harbor genes implicated in cancer, but evidence directly linking common risk variants within most of these loci to altered function of specific genes is lacking.
A r t i c l e s
Thus far, genome-wide association studies (GWAS) have identified 20 common, genome-wide significant melanoma susceptibility loci [1] [2] [3] [4] [5] [6] [7] [8] [9] , most of which do not seem to be explained by protein-coding variants. A subset of these loci harbor known pigmentation-related genes that mediate melanoma-associated phenotypes such as eye, hair, and skin color. Several loci harbor genes implicated in cancer, but evidence directly linking common risk variants within most of these loci to altered function of specific genes is lacking.
MacGregor et al. initially identified a melanoma risk locus tagged by rs3219090 on chromosome band 1q42.1 in an Australian case-control study at a nearly genome-wide level of significance (P = 9.3 × 10 −8 , odds ratio (OR) = 0.87, protective allele A) 8 . The association has since been replicated by multiple other studies 3, 10 , including most recently by a meta-analysis of 12,874 melanoma cases (rs1858550, P = 1.7 × 10 −13 ) 7 . Notably, the locus at 1q42.1 has also been associated with melanoma survival 11 , with the melanoma risk allele correlating with increased survival, an association that has since been replicated 12 . The region of association spans from 226.52 to 226.63 Mb (hg19) on chromosome 1, encompassing the entirety of the PARP1 (poly(ADP-ribose) (PAR) polymerase-1) gene (MIM 173870), and fine-mapping suggests that the association is best explained by a single-SNP model 3 .
A number of other genes is located in the vicinity of the association peak, but PARP1 has the most well-established role in cancer. PARP1 is best known for its role as a DNA repair enzyme and genotoxic sensor that functions in base-excision repair (BER), single-strand break repair, and double-strand break repair 13 . Once PARP1 binds to damaged DNA, its enzymatic function is activated and it covalently attaches PAR polymers to acceptor proteins, including histones and PARP1 itself 14 . PARP1 amplifies DNA damage signals, modifies chromatin structures to accommodate DNA damage response proteins, and further recruits DNA repair proteins 13, 15, 16 . Although PARP1 is not directly involved in repair of UV-signature mutations via nucleotideexcision repair, its role in the repair of DNA lesions induced by reactive oxygen species (ROS) is well established 17 . ROS are generated by UVA exposure 18 , are a byproduct of melanin production 19 , and seem to have a role in oncogene-induced senescence (OIS) 20, 21 . Aside from DNA repair, PARP1 functions in regulating gene expression by modifying chromatin structure, associating with promoters and enhancers, and acting as a transcriptional co-regulator 22, 23 . Many of these roles rely on PARP1 catalytic activity, but some are PARylation independent, as in the transcriptional co-regulator function for NF-κB and B-MYB 24, 25 .
In this study, we functionally characterized the 1q41.2 melanoma risk locus, demonstrating a consistent correlation of the riskassociated genotype with levels of PARP1 gene expression in tissues of melanocytic origin, identifying a gene-regulatory variant within the first intron of PARP1 and elucidating a role for PARP1 in melanocyte OIS via regulation of the melanocyte master regulatory transcription factor MITF.
RESULTS

The rs3219090 risk allele is correlated with high PARP1
We performed eQTL analysis to identify genes whose expression levels are correlated with the risk-associated genotype at 1q42.1 in tissues of the melanocytic lineage. Initially, we evaluated the correlation of rs3219090 genotype with expression of genes within ±1 Mb of this variant in 59 early-passage melanoma cell lines using expression microarray data. The results indicated that the rs3219090 risk allele is associated with higher levels of PARP1 expression (P = 1.4 × 10 −3 , linear regression; Fig. 1a) . Notably, PARP1 was the only gene in the region that passed a Bonferroni-corrected P-value threshold (with correction for 14 genes, P < 3.6 × 10 −3 ; Supplementary Table 1) , and this eQTL effect was subsequently validated by qPCR assay (P = 0.031, linear regression; Supplementary Fig. 1a) . We then sought independent replication of the eQTL effect on PARP1 and other nominally significant genes (P < 0.05) in publicly available RNA-seq data sets for melanoma-relevant tissues. When 409 melanoma tumors from The Cancer Genome Atlas (TCGA) Project (database of Genotypes and Phenotypes (dbGaP) accession phs000178.v9.p8) were tested, the melanoma risk allele at rs3219090 was again significantly correlated with higher PARP1 expression levels (P = 3.9 × 10 −3 , linear regression using copy number at the PARP1 locus as a covariate; Supplementary Fig. 1b) , while no other genes showed significant correlation (Supplementary Table 2 ). Similarly, the PARP1 eQTL effect was replicated in normal skin samples collected through the Genotype-Tissue Expression (GTEx) Project (dbGaP accession phs000424.v6.p1), including those derived from both sun-exposed skin (P = 2 × 10 −4 , linear regression, n = 302) and non-sun-exposed skin (P = 0.011, linear regression, n = 196) ( Supplementary Fig. 1c,d and Supplementary Tables 3 and 4) . Together, these data identified PARP1 as the strongest eQTL gene in the 1q42.1 locus whose expression displayed the most consistent correlation with genotype at the lead SNP in sample panels of melanocytic lineage as well as human skin.
To complement the eQTL data and rule out the possibility of any sample-specific confounding factors masking genotype effect, we performed allele-specific expression (ASE) analysis for PARP1 in samples carrying both the risk and protective alleles. Fourteen melanoma cell lines that are heterozygous for rs3219090 and harbor normal regional copy number were assayed using a quantitative allelic TaqMan assay for a synonymous coding surrogate SNP (rs1805414; r 2 = 0.98 with rs3219090 in 1000 Genomes Project Phase 3 European (EUR) data), where the allelic ratio was inferred from known ratios of allelic standards. The results demonstrated a significant allelic imbalance with a higher proportion of PARP1 expressed from the risk allele in the majority of the heterozygous cell lines (P = 1.2 × 10 −4 , two-tailed Wilcoxon signed-rank test; Fig. 1b) . A similar allelic imbalance was also observed when a subset of these cell lines was analyzed by RNAseq (P = 0.044, n = 7 copy-neutral and heterozygous cell lines, onesided one-sample t test; data not shown). In subsequent ASE analysis of PARP1 in TCGA and GTEx RNA-seq data sets, a higher allelic proportion of mapped reads was also observed for the risk allele across TCGA tumor samples (P = 0.011, two-tailed Wilcoxon signed-rank test, n = 48 copy-neutral and heterozygous tumor samples; Fig. 1c) , as well as in sun-exposed and non-sun-exposed skin tissues (GTEx; P = 1.16 × 10 −5 , n = 139 and P = 8.9 × 10 −5 , n = 69, respectively, twotailed Wilcoxon signed-rank test; Supplementary Fig. 1e,f) . These data demonstrate that the melanoma risk allele at rs3219090 is significantly associated with increased PARP1 expression in tissues of melanocytic origin and skin with consistency across multiple data sets.
Fine-mapping and functional annotation of candidate SNPs
Given that high PARP1 levels are correlated with the melanoma risk allele at rs3219090, we next sought to identify functional risk variant(s) that may influence PARP1 expression. Previously, finemapping of this locus in a large European population provided support for a model in which a single variant accounts for the association signal in this region 3 , a finding confirmed as part of the meta-analysis conducted by Law et al. 7 . We prioritized 65 variants that are highly correlated with the lead SNPs as candidate functional variants (r 2 > 0.6 with lead SNPs from the discovery study and meta-analysis 3,7 , rs3219090 and rs1858550, respectively; linkage disequilibrium (LD) based on 1000 Genomes Project Phase 3 data, EUR and CEU (northern and western European ancestry)). Given the absence of amino acid-changing PARP1 variants within this set of candidates, an absence of evidence for alternative splicing as a likely mechanism b a Figure 1 The melanoma risk-associated G allele at rs3219090 is correlated with increased PARP1 expression. (a) eQTL analysis was performed for rs3219090 using expression microarray data and SNP array genotypes derived from a panel of 59 early-passage melanoma cell lines (AA, n = 6; GA, n = 24; GG, n = 29). A significant eQTL effect was observed for PARP1, and the results are plotted by rs3219090 genotype (P = 1.4 × 10 −3 , linear regression). G is the risk allele and A is the protective allele at rs3219090. AU, arbitrary units. (b) Allelic ratios of PARP1 transcripts were measured in 14 copy-neutral melanoma cell lines heterozygous at both rs3219090 and a synonymous coding surrogate SNP (rs1805414; r 2 = 0.98 with rs3219090) using TaqMan genotyping assays. Allelic ratios were inferred from a known amount of allelic standards and are plotted as the ratio of PARP1 expression from the risk allele over expression from the protective allele (P = 1.2 × 10 −4 , two-tailed Wilcoxon signed-rank test; the average values of PCR triplicates are considered as a single data point). (c) Allelic ratios of PARP1 transcripts were measured using RNA-seq data from 48 copy-neutral TCGA skin melanoma samples heterozygous at both rs3219090 and rs1805414. Mapped numbers of RNA-seq reads encompassing each allele of rs1805414 were used to calculate allelic ratios (P = 0.011, two-tailed Wilcoxon signed-rank test). In b and c, the solid line corresponds to a 1:1 ratio and the dotted line represents the median ratio.
A A r t i c l e s (Supplementary Note), and considerable evidence for allelic differences in PARP1 expression levels, we focused on variants located within annotated melanocyte-or melanoma-specific cis-regulatory elements using data from the Encyclopedia of DNA Elements (ENCODE) 26 Table 6 ). On the basis of these data, we proceeded with functional characterization of these four candidates ( Supplementary Fig. 2 and Supplementary Table 6 ).
An intronic indel displays allelic transcriptional activity
We assessed all four candidate functional variants for gene-regulatory potential using luciferase reporter assays, as well as for allelic patterns of protein binding via electrophoretic mobility shift assays (EMSAs). For these assays, we sought to identify variants that displayed (i) transcriptional activation consistent with ENCODE annotation, (ii) higher activity for the risk allele consistent with the eQTL data, and (iii) allelespecific protein binding. Of the four candidate variants, only rs144361550, a GGGCCC indel variant, met all these criteria (Figs. 2 and 3, and Supplementary Figs. 4-6; summarized in Supplementary  Table 7) . Namely, luciferase assays conducted in a melanoma cell line demonstrated that the genomic region around rs144361550 exhibits strong transcriptional activity for both long (905-bp fragment covering the larger DHS region; ~17-to 20-fold higher expression than control levels) and short (22-or 28-bp fragment covering the GGGCCC repeats; ~1.7-to 2.5-fold higher expression than control levels) cloned fragments ( Fig. 3a) , with the risk-associated deletion allele exhibiting higher reporter activity than the insertion allele (30-45% higher). In primary melanocytes, where transfection efficiency is considerably lower, allelic activity was not observed, but the long deletion and insertion fragments displayed weak but significant transcriptional activity (P = 1.2 × 10 −3 and 5.9 × 10 −4 , respectively, two-tailed, paired t test; Fig. 3c ). EMSAs using nuclear extract from melanoma cell lines or cultured primary human melanocytes displayed preferential binding of nuclear proteins to the insertion allele ( Fig. 3b,d ). Given the potential for miscalling the genotype of this functional indel, we directly genotyped rs144361550 in a large reference set to confirm LD with the lead SNP (Supplementary Figs. 7 and 8, Supplementary Tables 8 and 9, and Supplementary Note).
To identify proteins that bind rs144361550 in an allele-preferential manner, we used quantitative mass spectrometry employing dimethyl label swapping [28] [29] [30] . Mass spectrometry using melanoma cell line extract identified exclusively insertion-allele-preferential interactors, the majority of which are not conventional transcription factors, including the RECQL helicase (Fig. 4a) . Although two transcription factors previously found by the ENCODE Project to localize to the region overlapping rs144361550 via chromatin immunoprecipitation (ChIP) were found to bind rs144361550 probes (TFAP2A and ZBTB7A), neither did so in an allele-preferential manner (data not shown), in line with the observation that rs144361550 creates no new sequence motifs but rather extends a poly(G) repeat stretch. We then performed a series of antibody supershift assays and EMSAs using purified recombinant protein for multiple candidates and validated that RECQL is an unequivocal allele-preferential binder of rs144361550 (Fig. 4b, Supplementary Fig. 9 , and Supplementary  Table 10 ). ChIP assays indicated that RECQL indeed binds to the PARP1 indel region in melanoma cells and primary human melanocytes carrying an insertion allele ( Fig. 4c and Supplementary Fig. 10 ). We also performed a series of in silico and in vitro assays testing for alternative DNA secondary structure formation (G quadruplex, or G4), with the results suggesting a RECQL-specific allelic binding mechanism rather than one through G4 ( Supplementary Figs. 11-13 , Supplementary Tables 10 and 11, and Supplementary Note).
Ectopic expression of RECQL at a moderate level in three melanoma cell lines carrying insertion or deletion alleles using lentiviral transduction resulted in a mild increase in PARP1 transcription (Fig. 4d) . We then performed luciferase assays for rs144361550 with or without RECQL overexpression in cells with low baseline levels of RECQL relative to melanomas (HEK293FT cells). At the basal level, the insertion and deletion alleles did not display differential luciferase activity, but upon RECQL overexpression the significant allele-specific transcriptional activity we previously observed in melanoma cell lines was recapitulated (Fig. 4e) . Together, these data suggest that RECQL may Individual P values are shown or *P < 0.05 against control (two-tailed, paired t test). Two (a) and three (c) independent cell cultures and transfections of n = 3 biological replicates were combined; data are presented as the median with range, 75th and 25th percentiles, and each data point is shown. Ctrl, minimal promoter control; Del, deletion (risk) allele construct; Ins, insertion (protective) allele construct. (b,d) EMSAs were performed using biotin-labeled double-stranded oligonucleotides for the deletion (risk; Del, D) and insertion (protective; Ins, I) alleles of rs144361550 and nuclear extracts from melanoma cell lines UACC2331 and UACC457 (b) and primary melanocytes (d). The sequences shown in b for the 22-bp deletion and 28-bp insertion probes were used for both b and d (bold bases highlight potential G4-structure-forming nucleotides). 50×, 200×, or 500× molar excess of unlabeled competitor was added in specified lanes.
A r t i c l e s have a role in PARP1 allelic expression in cells of melanocytic lineage through the melanoma risk-associated indel rs144361550.
PARP1 facilitates melanocyte growth and transformation
Given that the risk allele at rs3219090 is associated with increased levels of PARP1 expression, we tested whether increased PARP1 levels could lead to altered cellular phenotypes relevant to melanomagenesis. As BRAF V600E -induced senescence is well accepted as a barrier to malignant transformation in early events of melanomagenesis [31] [32] [33] and ROS seem to represent a potential functional link between PARP1 and OIS 21 , we examined whether elevated PARP1 modulates OIS by overexpressing PARP1 in human primary melanocytes expressing oncogenic BRAF (BRAF V600E ). Consistent with published results, ectopic expression of BRAF V600E in human melanocytes induced robust arrest of cell growth and proliferation, accompanied by heterochromatic H3K9me3 focus formation (Fig. 5a-c and Supplementary Fig. 14) and a moderate increase in β-galactosidase activity ( Supplementary  Fig. 15 ), both hallmarks of OIS. Overexpression of PARP1 before induction of BRAF V600E expression, however, prevented the cell cycle arrest and H3K9me3 focus formation as well as β-galactosidase activity observed in melanocytes expressing BRAF V600E alone (Fig. 5a-c and Supplementary Figs. 14 and 15) , demonstrating rescue from BRAF V600E -induced senescence. Crystal violet staining of cells 3 weeks after the initiation of PARP1 expression indicated that PARP1 by itself can also increase cell proliferation in the absence of BRAF V600E , suggesting an effect on cell proliferation by PARP1 (Fig. 5a ). PARP1 consistently exerted weak but significant effects on cell proliferation and mediated OIS reversal even at a moderate induction level (~1.5-fold; Supplementary Fig. 16 ), recapitulating the subtle allelic expression differences observed in melanomas carrying risk versus protective alleles. Several oncogenes, including MYC 34 and PIK3CA 33 , have been reported to stimulate malignant transformation in melanoma cells by abrogating OIS and restarting cell proliferation. To further evaluate whether PARP1 can stimulate malignant transformation by affecting melanocyte proliferation, we examined the effect of PARP1 on the anchorage-independent growth of TERT-immortalized human melanocytes (p'mel cells 35 ) by soft-agar assay. PARP1 cooperated with BRAF V600E to enhance colony formation of p'mel cells in soft agar, similar to the previously reported effect of MITF 35 , albeit to a lesser degree (Fig. 5d,e) . Thus, like deregulated MITF expression, increased expression of PARP1 can both rescue human melanocytes from BRAF V600E -induced senescence and further transform them. Most of the well-characterized functions of PARP1, including those involving DNA repair, are closely linked to its poly(ADP-ribosyl)ation A r t i c l e s activity. We therefore tested whether PARP1-mediated rescue of melanocytes from BRAF V600E -induced OIS is dependent on PARP1 catalytic activity. Melanocytes overexpressing both PARP1 and BRAF V600E were treated with the PARP1 inhibitor BYK204165 (ref. 36) , and the inhibition of PAR activity was confirmed by immunoblotting with an antibody recognizing PAR (Fig. 6a) . BYK204165 treatment did not block the cell proliferation effect of PARP1 in BRAF V600E -expressing cells, as shown by similarly increased cell growth in crystal violet staining (Supplementary Fig. 17a ), an increased percentage of 5-bromodeoxyuridine (BrdU)-positive cells, and a reduced G0/G1 population in PARP1-expressing cells (Fig. 6b) , nor did it affect H3K9me3 focus formation ( Supplementary  Fig. 17b) . We also tested a catalytically inactive mutant version of PARP1 (refs. 37-39) for effect on melanocyte growth and proliferation ( Supplementary Fig. 18a-d) , which resulted in similar phenotypes to those observed using BYK204165.
PARP1 transcriptionally activates MITF
To begin to understand the mechanism of PARP1-mediated senescence rescue, we first examined changes in ROS content in BRAF V600E -and/or PARP1-overexpressing melanocytes. We observed a minor increase in ROS content from BRAF V600E expression, but we did not detect meaningful changes in ROS content from PARP1 in our melanocyte system (data not shown). We then turned our attention to melanocyte-lineage survival oncogene MITF, which is frequently amplified in malignant melanomas and can transform melanocytes in the context of BRAF V600E (ref. 35) . Previous studies have observed that MITF expression is inhibited by oncogenic BRAF V600E in melanomas 40 . Consistent with this finding, we demonstrate that persistent activation of the mitogen-activated protein kinase (MAPK) pathway by BRAF V600E also suppressed MITF levels in primary melanocytes (Fig. 6a) . Notably, PARP1 induction, at either a strong ( Fig. 6a and Supplementary Fig. 19 ) or more modest ( Supplementary  Fig. 16e,f) level, increased MITF at both the mRNA and protein levels, in a PARylation-independent manner ( Fig. 6a and Supplementary  Fig. 18d-f) . PARP1 also partially restored MITF expression in BRAF V600E -expressing melanocytes, suggesting a link between OIS rescue and MITF restoration ( Fig. 6a and Supplementary Figs. 16e ,f, 18d-f, and 19). Consistent with this finding, we observed a weak but significant positive correlation between PARP1 and MITF transcript levels ( Supplementary Fig. 20 ) in 409 melanoma samples from TCGA (Pearson's r = 0.198, P = 5.7 × 10 −5 ) as well as in the smaller subset of 189 tumors that were copy neutral at the MITF locus (Pearson's r = 0.252, P = 4.8 × 10 −4 ). To address potential issues with tumor heterogeneity and random factors driving this correlation in melanomas, we also looked at correlation in our early-passage melanoma cell lines. Although we did not observe a significant correlation in the full set of 59 cell lines (Pearson's r = 0.15, P = 0.26; Supplementary Fig. 21a ), A r t i c l e s when we further subdivided these lines into MITF-high and MITF-low groups to account for distinct cellular states signified by MITF levels 41 , a strong correlation between PARP1 and MITF levels was observed only in the MITF-high group (Pearson's r = 0.560, P = 5.5 × 10 −3 , n = 23; P = 6.6 × 10 −3 with adjustment for MITF copy number; Supplementary Fig. 21b) . A trend of association with PARP1 levels was also observed in a subset of MITF target genes ( Supplementary  Fig. 21c,d and Supplementary Table 12) . MITF is an essential melanocyte-survival gene, and we therefore could not directly test whether MITF mediates PARP1 senescence rescue by knocking down MITF in our system. While MITF depletion by short hairpin RNA (shRNA) dramatically reduced melanocyte growth approximately 2 weeks after initiation of knockdown (Fig. 6c,d) , at an earlier time point (day 9 after infection), we noticed that MITF depletion itself introduced a weak but distinct senescence-associated H3K9me3 phenotype (Fig. 6e) , as previously reported 42 . Interestingly, in the context of MITF knockdown, PARP1 senescence rescue was not observed in terms of partial reversal of H3K9me3 focus formation (Fig. 6e) . These results suggest that PARP1 function in senescence rescue is likely upstream of MITF expression.
Given that PARP1 activates MITF at the mRNA level, we performed ChIP analysis to determine whether PARP1 directly localizes to the promoter of the melanocyte-specific MITF-M isoform 43, 44 in human primary melanocytes. ChIP experiments were performed via overexpression of PARP1 in melanocytes, as well as in melanocytes expressing endogenous levels of PARP1. Among seven primer sets spanning the MITF-M promoter region (−1,263 to +172 bp with respect to the transcription start site; TSS), the two that are more proximal to the TSS displayed the most significant enrichment, indicating PARP1 binding (~8-to 19-fold above IgG background at endogenous levels, Primer4 and Primer5, from −587 to −136 bp; Fig. 7) . Localization of PARP1 to the MITF-M promoter was observed both with PARP1 overexpression and endogenous levels, whereas no detectable enrichment was observed when PARP1 was knocked down using an shRNA (data not shown). Notably, the region where PARP1 localizes overlaps with consensus binding sites for previously known transcriptional regulators of the MITF-M promoter, including SOX10, TCF/LEF, and CRE (Fig. 7) , and a putative PARP1 binding motif 45 was also predicted in this core region (Online Methods).
To assess whether PARP1 directly regulates MITF transcription, we performed luciferase reporter assays using constructs containing Figure 6 MITF expression is restored in primary human melanocytes coexpressing PARP1 and BRAF V600E in a PARylation-independent manner, concurrent with partial reversal of senescence phenotypes. (a) Immunoblot detection of MITF (long and short exposures), BRAF, PARP1, and PAR. Primary human melanocytes were coinfected with viruses expressing PARP1 and BRAF V600E followed by treatment with the PARP inhibitor BYK204165. Cell extract was generated at day 13 after initial infection with the PARP1 construct. Blot images have been cropped. (b) BrdU flow cytometry of primary human melanocytes coinfected with viruses expressing PARP1 and BRAF V600E alone or together with virus expressing MITF shRNA or followed by treatment with the PARP inhibitor BYK204165. (c) Crystal violet staining of melanocytes coinfected with viruses expressing PARP1 and BRAF V600E alone or together with virus expressing MITF shRNA. Primary melanocytes were first infected with pIN20-PARP1 or empty pIN20 vector concurrently with pLKO-shRNA-MITF-M or empty pLKO vector followed by G418 selection and doxycycline induction. Cells were then infected with HIV-CSCG-BRAF V600E or empty HIV-CSCG vector at day 6 after pIN20-PARP1 infection followed by blasticidin selection. A representative crystal violet staining image (n = 3 technical replicates) is displayed at day 17 of infection. (d) Quantification of solubilized crystal violet staining by measuring absorbance at 540 nm (OD 540 ) at day 17 of infection is plotted. Data are presented as the median with range (n = 3 technical replicates; t test assuming unequal variance; a representative set from three experiments is shown). (e) PARP1-mediated partial reversal of BRAF V600E -induced H3K9me3 focus formation in melanocytes is blocked by knockdown of MITF. H3K9me3 staining was performed at day 13 after initial infection. Scale bars, 10 µm.
A r t i c l e s
MITF-M promoter regions 46 . Alteration of PARP1 levels via overexpression or shRNA-mediated knockdown failed to modulate reporter activity ( Supplementary Fig. 22 ), suggesting a potential epigenetic role for PARP1 in regulation of the MITF-M locus that is not recapitulated in ectopic expression of a reporter gene. Bisulfite sequencing of two assayable CpGs near the MITF-M TSS 47 indicated that introduction of BRAF V600E does not their methylation status ( Supplementary  Fig. 23 ), speaking against DNA-methylation-mediated regulation in this context. Examination of a promoter histone mark, H3K4me3, by ChIP showed that H3K4me3 is enriched in the MITF-M proximal promoter when PARP1 is expressed either ectopically or at endogenous levels ( Supplementary Fig. 24a ), but is diminished upon knockdown of PARP1 expression (Supplementary Fig. 24b) . Furthermore, expression of BRAF V600E resulted in diminished H3K4me3 signal in the MITF-M promoter, but this signal was restored to its usual high levels upon coexpression of PARP1 (Supplementary Fig. 24c ). ChIP analyses using antibodies recognizing the C-terminal domain (CTD) of RNA polymerase II (Pol II) or the Pol II CTD phosphorylated at serine 5 demonstrated that Pol II and its initiation signature, serine 5 phosphorylation, are both enriched near the MITF-M TSS at endogenous PARP1 levels but diminished upon PARP1 knockdown (Supplementary Fig. 25 ). These results are consistent with a model in which PARP1 influences MITF-M promoter activity and influences MITF levels via transcriptional regulation.
DISCUSSION
In this study, eQTL and ASE analyses suggest PARP1 as the susceptibility gene underlying the melanoma risk locus on chromosome band 1q42.1. When we evaluated the set of genes in the region ±1 Mb with respect to the lead melanoma risk SNP (rs3219090) to account for potential long-range regulation, we observed a highly reproducible eQTL effect on PARP1 but not other nearby genes. The correlation between the risk allele and higher levels of PARP1 expression was highly reproducible across multiple melanoma-relevant tissues, including early-passage melanoma cell lines, melanoma tumors, and human skin biopsies, in both eQTL and ASE analyses. Although eQTL and ASE analyses cannot completely rule out a potential role for other genes within the larger genomic region surrounding the GWAS peak association signal, these data strongly implicate PARP1 as functionally mediating melanoma risk at this locus. Although this region is relatively small in size, 65 variants are nonetheless strongly correlated (r 2 > 0.6) with the lead GWAS SNP. To efficiently prioritize functional candidates, we took advantage of potential gene-regulatory regions annotated in human melanocyte and melanoma samples by the ENCODE and Roadmap Epigenomics projects. We chose to focus on variants located in the most consistently annotated regulatory elements across different individuals and cellular conditions because of the consistent eQTL and ASE data observed in both melanocytes and melanomas. Subsequent characterization of these candidate variants highlighted a single variant, rs144361550, as a strong functional candidate. Of the variants tested, only rs144361550 demonstrated both allele-specific transcriptional activity and protein binding patterns in a manner consistent with the observed pattern of genotype-expression correlation. Although these data provide support for rs144361550 as a functional melanoma risk variant influencing PARP1 expression levels, they nonetheless cannot rule out other variants in this region as also contributing to the observed correlation between PARP1 levels and genotype.
Our unbiased approach using quantitative mass spectrometry identified RECQL as a protein binding with allele preference to rs144361550. Notably, RECQL binding to rs144361550 does not seem to be driven by sequence specificity but rather is regulated by DNA secondary structure. The genomic sequence encompassing rs144361550 suggested G4-forming potential (Supplementary Table 11) , which might explain a regulatory role 48 , but our in vitro assays failed to provide definitive evidence of G4 structure for either the insertion or deletion allele. However, formation of another differential structural motif, such as a transient hairpin structure (formed by single-stranded sequences; Supplementary Table 13) or a locally perturbed doublehelix structure at the hexanucleotide-repeat domain 49 , inducing DNA bending and serving as a recognition motif for allele-specific protein binding 50 , cannot be excluded.
Although PARP1 is most well known for its role in DNA repair, thus far, GWAS have identified this region only for melanoma susceptibility (NHGRI GWAS Catalog; see URLs), suggesting a potential melanoma-specific role for PARP1. Indeed, ectopic expression of PARP1 led to increased melanocyte proliferation, both alone and in the presence of the oncogenic mutated version of BRAF (BRAF V600E ). BRAF V600E is found in most melanocytic nevi 51 , and, as reported earlier 31 , its overexpression in primary melanocytes led to markedly decreased cell proliferation as well as H3K9me3 focus formation, a hallmark of cellular senescence 52 . Our data show that these A r t i c l e s 53, 54 . Although we did not exhaustively explore all the major functions of PARP1, including DNA repair and inflammation, in the context of melanomagenesis, our findings highlight a previously undescribed role for PARP1 in a melanocyte-specific context, providing a potential link between a susceptibility gene and a lineage-specific oncogene. Most well-established functions of PARP1 are dependent on poly(ADP-ribosyl)ation activity, including its role in DNA damage response and repair. Whereas some transcriptional co-regulator functions of PARP1 do not require its enzymatic activity 24, 25 , the role of PARP1 in chromatin structure modification mainly relies on NAD + -dependent association with nucleosomes 55 or PARylation of histones and chromatin modulators such as the histone demethylase KDM5B 56, 57 . Notably, the effects of PARP1 expression on melanocyte proliferation, BRAF V600E -induced senescence, and restored MITF-M expression do not seem to depend on the catalytic activity of PARP1. Interestingly, PARP1-mediated MITF-M upregulation seems to involve chromatin modulation, as the promoter histone mark H3K4me3 is markedly enriched near the TSS of MITF-M upon PARP1 expression relative to the depleted state in BRAF V600E -expressing melanocytes. Although this observation suggests a potential PARylation-independent chromatin modulation function, further investigation is required to establish a causal relationship and molecular link. 
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Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. DAPI (Invitrogen). Images were examined and processed using a Zeiss LSM 700 confocal microscope with total 630× magnification. Representative images are shown. To measure H3K9me3 levels by immunoblotting, total histone was extracted using HCl following a standard protocol (Abcam) and probed with rabbit antibody to histone H3 (61277, Active Motif) or rabbit antibody to histone H3K9me3 (ab8898, Abcam); ratios of H3K9me3 to total histone H3 did not correlate with H3K9me3 focus formation (Supplementary Fig. 26 ).
Colony formation assays. Anchorage-independent growth was assayed with p'mel/BRAF V600E cells (provided by H. Widlund, Dana-Farber Cancer Institute). Briefly, 2,500 cells were mixed in HAMF12 medium supplemented with 10% FBS containing 0.4% SeaKem LE agarose from Lonza and plated on top of a bottom layer with 0.65% agarose prepared in the same HAMF12 medium in a six-well plate. After the agarose solidified, each well was covered with 0.5 ml of feeding medium, which was refreshed twice a week. Colonies were counted and imaged 3-4 weeks after seeding under a regular microscope with total magnification of 40×. Colonies were counted from three wells for each condition, and significant differences from the control were assessed by t test assuming unequal variance.
Chromatin immunoprecipitation of PARP1, H3K4me3, and Pol II. Primary human melanocytes (HEMn-LP, Invitrogen) were fixed with 0.1% formaldehyde when 80-90% confluent. About 1 × 10 7 cells were sheared by sonication using a Bioruptor (Diagenode) on the high setting for ten cycles with 20 s ON and 30 s OFF. Chromatin was purified and immunoprecipitated following the instructions of the Active Motif CHIP-IT High-Sensitivity kit. 5-10 µg of sheared chromatin was used for each immunoprecipitation with antibody against PARP1 (46D11; 9532, Cell Signaling Technology), H3K4me3 (ab8580, Abcam), Pol II CTD (17-672, Millipore), or Pol II CTD phosphorylated at Ser5 (ab5408, Abcam) or with normal rabbit IgG (ab46540, Abcam) or normal mouse IgG (17-672, Millipore). Purified immunoprecipitated DNA was assayed by SYBR Green qPCR for enrichment of target sites across the MITF-M promoter using the primers listed in Supplementary Table 14. Statistical analyses. All cell-based experiments were repeated at least three times with separate cell cultures, except for those shown in Figure 3a (repeated twice), Figure 4d ,e (six technical replicates), and Figure 5d ,e (repeated twice). When a representative set is shown, replicate experiments displayed similar patterns. For all plots, individual data points are shown with the median or mean, range (maximum and minimum), and 25th and 75th percentiles (where applicable). The statistical method, number of data points, and number and type of replicates are indicated in each figure legend.
Data availability. The data generated during the current study have been deposited in GEO (Edgar et al., 2002) under accession GSE99221 (superseries), which includes GSE99193 (genotype data) and GSE78995 (expression data).
